Amgen Inc. vs BP plc: Strategic Comparison

This in-depth comparison examines Amgen Inc. and BP plc across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating BP plc, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and BP plc is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $189.3B for BP plc, while their respective market capitalizations stand at $228.2B and $112.2B. Amgen Inc. is headquartered in United States and BP plc in United Kingdom, and those different home markets shape how each company competes.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

BP plc: BP plc began as the Anglo-Persian Oil Company in 1909, became the British Petroleum Company in 1954, merged with Amoco in 1998 and has been called BP p.l.c. since 2001. It explores for and produces oil and gas, refines crude, sells fuels and lubricants, and trades energy in 61 countries. The 2010 Deepwater Horizon blowout, which killed 11 workers, cost BP more than $65 billion and forced years of asset sales. In 2020 BP pledged to shrink oil and gas output and build a large renewables business; by 2025 weak returns and investor pressure led it to reverse much of that plan. In 2026 it operates as a leaner oil and gas company under CEO Meg O'Neill and chair Ian Tyler.

Amgen Inc. and BP plc pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and BP plc.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

BP plc business model: BP earns money at each stage of the oil and gas chain. Upstream, it finds and produces crude oil and natural gas in the Gulf of America (Gulf of Mexico), the North Sea, Brazil, Iraq, Azerbaijan, Oman, Trinidad, Egypt and US onshore basins; output averaged 2.3 million barrels of oil equivalent per day in Q1 2026 and 2.2 million in Q2 2026. Downstream, it refines crude at plants such as Whiting, Indiana, and sells fuels, lubricants, aviation fuel and convenience goods through brands including BP, Amoco, ARCO, Aral, ampm, Thorntons and TravelCenters of America. A supply, trading and shipping arm moves crude, refined products, gas, LNG and power between markets and is often the swing factor in quarterly profit, as it was in Q2 2026. From July 1, 2026 BP reports through two segments, Upstream and Downstream, replacing the three-segment structure (gas & low carbon energy; oil production & operations; customers & products) created in 2020. Low-carbon activities such as Archaea Energy's renewable natural gas, bp pulse EV charging and a 50% stake in offshore wind venture JERA Nex bp continue at a smaller scale.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of BP plc.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

BP plc competitive advantage: BP's edge rests on three things that are hard to copy. The first is deepwater know-how and infrastructure, including five operated production hubs in the Gulf of America and a growing position offshore Brazil. The second is one of the industry's largest supply, trading and shipping businesses, which turned volatile oil and gas prices into profit in Q2 2026. The third is a downstream network of refineries, fuel brands and convenience sites in the US, UK and Germany. Exploration has also improved: BP describes its August 2025 Bumerangue find in Brazil's Santos Basin as its largest discovery in 25 years.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and BP plc each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

BP plc growth strategy: BP's current strategy dates from its February 2025 reset, which raised upstream oil and gas investment to about $10 billion a year, cut planned spending on transition businesses to $1.5-2 billion a year, and set targets of $20 billion of divestments and $14-18 billion of net debt by 2027. Meg O'Neill has gone further since April 2026: two business segments instead of three from July 1, about 700 non-frontline job cuts reported in July, completion of the Gelsenkirchen refinery sale to Klesch Group in August, and continued exploration in Brazil and the Gulf of America. Low-carbon work continues where BP sees returns, mainly renewable natural gas, EV charging and its offshore wind joint venture with Japan's JERA.

A closer look at the financial trajectory of Amgen Inc. and BP plc rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

BP plc: BP's 2025 revenue was $189.3 billion, nearly flat on 2024's $189.2 billion and below 2023's $210.1 billion. Underlying replacement-cost profit, the measure BP and analysts use to strip out inventory effects and one-off items, fell to $7.5 billion from $8.9 billion in 2024 as oil prices weakened, and profit attributable to shareholders was just $55 million after fourth-quarter charges. Operating cash flow was $24.5 billion and net debt ended the year at $22.2 billion. In February 2026 the board suspended buybacks so surplus cash could go to the balance sheet. Higher oil and gas prices linked to the conflict involving Iran, plus strong trading, lifted underlying replacement-cost profit to $3.2 billion in Q1 2026 and $5.7 billion in Q2 2026. With the Q2 results BP raised its quarterly dividend 4% to 8.66 cents per share and guided to $13.5-14 billion of capital spending for 2026.